Patients at risk for C. difficile Infection or opioid events can be difficult to detect.
Sentri7 AI+ empowers teams to improve patient care by finding at-risk patients earlier and providing evidence-based guidance to proactively addressing those risks.

Sentri7's AI+ Enhancements for Stewardship

Antimicrobial Stewardship - AI improves C. difficile infection risk detection with a CDI Risk Score
Empower pharmacy teams to move from reactive care to proactive care to prevent C. difficile infections and improve stewardship performance.

  • A multidisciplinary team-validated AI model - Physicians, epidemiologists, antimicrobial stewardship experts and data scientists across Wolters Kluwer analyzed millions of deidentified records to cultivate a validated AI model for assessing C. difficile patient risk.
  • Sentri7's AI-powered surveillance and predictive CDI algorithm continuously monitor the inpatient hospital population in real-time to identify at-risk patients sooner.

  • Evidence-based rules track patients at elevated risk and suggested actions help clinical teams put evidence into practice sooner to proactively prevent C. difficile infections.

  • Patients’ risk scores automatically update as the patient condition and risk factors change, allowing clinicians to address modifiable risk factors at appropriate stages.

Opioid Stewardship - AI delivers a real-time Morphine Milligram Equivalent (MME) calculation 
Ensure compliance with the Joint Commission's standards, improve inpatient opioid use and patient safety.

  • Real-time and precise MME calculations are powered by AI - Sentri7 leverages machine learning to analyze complex dosing data sets to automatically calculate patient-specific, real-time Morphine Milligram Equivalent (MME).

  • Sentri7 uses AI to continuously analyze the MME calculation over 24-hours and automatically updates it based on opioid dose administrations provided to the patient.

  • Evidence-based rules, combined with AI-powered tools and insights, identify and monitor patients at risk for opioid-related adverse events, as well as opportunities to discontinue use or change agents to improve patient care and safety.

Learn More About Sentri7 AI+!

Learn More Via Our Expert Insights